Drug intelligence / Profile preview

Aluminium acetoacetate

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Aluminium acetoacetate is an aluminum-containing antacid used for the treatment of acid-related disorders and hyperphosphatemia (elevated phosphate levels in the blood). It acts by neutralizing gastric acid in the stomach and binding dietary phosphate to reduce its absorption. Aluminium compounds decrease gastrointestinal motility and are commonly used as antacids or phosphate binders in clinical practice[1][2][4][8]. The drug is considered experimental and has not been widely approved for clinical use.

Brand names: Alumichelate AW
Other names: aluminum acetoacetatealuminum;3-oxobutanoateAluminum, tris(3-oxobutanoato-O1,O3)-ALUMINIUM ACETOACETATE [WHO-DD]2,8,13-trihydroxy-4,10,15-trimethyl-1lambda3,5,7lambda3,11,12lambda3,16-hexaoxa-6-aluminaspiro(5.56.56)hexadeca-1,7,12-triene-6,6,6-tris(ylium)

Beyond the preview

Go deeper on Aluminium acetoacetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aluminium acetoacetate.

Explore the full profile